The Boston Examiner
SEE OTHER BRANDS

The most trusted news from Massachusetts

The Boston Examiner: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Boston Examiner.

Press releases published on May 6, 2025

Flywire Reports First Quarter 2025 Financial Results

Flywire Reports First Quarter 2025 Financial Results

First Quarter Revenue Increased 17.0% Year-over-Year First Quarter Revenue Less Ancillary Services Increased 16.8% Year-over-Year Previous Fiscal Year 2025 guidance reaffirmed BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Flywire Corporation (Nasdaq: FLYW) (“ …

Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025

Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025

IRVINE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 2025 and raised its …

Mercury Systems Reports Third Quarter Fiscal 2025 Results

Mercury Systems Reports Third Quarter Fiscal 2025 Results

Q3 FY25 Bookings of $200.4 million; trailing-twelve-month book-to-bill of 1.1 Backlog of $1.34 billion; up 4% year-over-year Q3 FY25 Revenue of $211.4 million; GAAP net loss of $19.2 million; and adjusted EBITDA of $24.7 million Operating Cash Flow of $30. …

Keros Therapeutics Reports Recent First Quarter 2025 Financial Results

Keros Therapeutics Reports Recent First Quarter 2025 Financial Results

LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients …

Voyager Reports First Quarter 2025 Financial and Operating Results

Voyager Reports First Quarter 2025 Financial and Operating Results

– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg – – Recent Voyager data on VY7523 and VY1706 presented at AD/PD™ …

Lantheus Announces Sale of SPECT Business to SHINE Technologies

Lantheus Announces Sale of SPECT Business to SHINE Technologies

Enables Lantheus to focus on innovative radiopharmaceuticals, while maximizing the value of its SPECT business SHINE will acquire products TechneLite®, NEUROLITE®, Xenon Xe-133 Gas, and Cardiolite® BEDFORD, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lantheus …

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on May 1, 2025, it awarded an …

Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

WATERTOWN, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic …

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

NEWTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the …

UFP Technologies Announces Record Q1 Results

UFP Technologies Announces Record Q1 Results

NEWBURYPORT, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), a designer and custom manufacturer of comprehensive solutions primarily for the medical market, today reported net income of $17.2 million or $2.21 per diluted …

Unveiling the Future of Trailer & Container Security: The Tive Security Seal

Unveiling the Future of Trailer & Container Security: The Tive Security Seal

BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Tive, the global leader in supply chain and logistics visibility technology, today announced that the company has partnered with TydenBrooks, the global leader in security seals and solutions, to deliver the Tive …

Imprivata Wins Global InfoSec Awards in Passwordless Authentication and Third Party Risk Categories

Imprivata Wins Global InfoSec Awards in Passwordless Authentication and Third Party Risk Categories

WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Imprivata, the digital identity company for life- and mission-critical industries, today announced that the company has won two Global InfoSec Awards 2025, presented by Cyber Defense Magazine during RSA …

Salary.com Announces Partnership with Texas Hospital Association

Salary.com Announces Partnership with Texas Hospital Association

WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Salary.com, the global leader in compensation technology and data, today announced its partnership with the Texas Hospital Association (THA), the leadership organization and principal advocate for the state’ …

Alpha Tau to Participate in May Investor Conferences

Alpha Tau to Participate in May Investor Conferences

JERUSALEM, May 06, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will presentation in …

Candel Therapeutics to Present at Upcoming Investor Conferences

Candel Therapeutics to Present at Upcoming Investor Conferences

NEEDHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, …

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David …

Avalyn Announces Multiple Presentations on AP01 and AP02 for Pulmonary Fibrosis at the American Thoracic Society 2025 International Conference

Avalyn Announces Multiple Presentations on AP01 and AP02 for Pulmonary Fibrosis at the American Thoracic Society 2025 International Conference

Topline Results from the AP02 (Inhaled Nintedanib) Phase 1 Clinical Trials Among the Company’s Five Poster Presentations 4.5 Year Long-Term Safety and Efficacy Data Supporting AP01 (Inhaled Pirfenidone) from the ATLAS Open-Label Extension Trial to be …

Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Dose optimization and RP2D determination on schedule for completion in Q4 2025 for the Nectin-4 ADC CRB-701 in HNSCC, cervical and mUC tumors SAD/MAD study on schedule for completion in Q3 2025 for the anti-obesity CB1 inverse agonist CRB-913 Dose …

Compass Therapeutics to Participate in Upcoming May Investor Events

Compass Therapeutics to Participate in Upcoming May Investor Events

BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the …

Cogent Biosciences Reports First Quarter 2025 Financial Results

Cogent Biosciences Reports First Quarter 2025 Financial Results

Three Registration-Directed Top-line Data Readouts Remain on Track in 2025: SUMMIT in NonAdvanced SM expected in July, APEX in Advanced SM expected in second half of the-year and PEAK in GIST expected by end of year Ended 1Q 2025 with $245.7 million in …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service